Publications



DSUVIA™

1. Primary Manuscript for SAP301
Minkowitz HS, Leiman D, Melson T, Singla N, Didonato KP, Palmer PP. Sufentanil Sublingual Tablet 30 mcg for the Management of Pain Following Abdominal Surgery: A Randomized, Placebo-Controlled, Phase 3 Study. Pain Pract. 2017;17(7):848-858.

http://onlinelibrary.wiley.com/doi/10.1111/papr.12531/abstract

2. Primary Manuscript for SAP302 (open-label study)
Miner JR, Rafique Z, Minkowitz HS, DiDonato KP, Palmer PP. Sufentanil sublingual tablet 30 mcg for moderate-to-severe acute pain in the ED. Am J Emerg Med. 2018;36(6):954-961.

https://www.sciencedirect.com/science/article/pii/S0735675717308860

3. Primary Manuscript for SAP303 (open-label study)
Hutchins JL, Leiman D, Minkowitz HS, Jove M, DiDonato KP, Palmer PP. An Open-label Study of Sufentanil Sublingual Tablet 30 mcg in Patients with Postoperative Pain. Pain Med. 2018;19(10):2058-2068.

https://academic.oup.com/painmedicine/article/19/10/2058/4590264

4. DSUVIA PK Manuscript
Fisher DM, Chang P, Wada R, Dahan A, Palmer PP. Pharmacokinetic Properties of a Sufentanil Sublingual Tablet Intended to Treat Acute Pain. Anesthesiology.2018;128(5):943-952.

http://anesthesiology.pubs.asahq.org/article.aspx?articleid=2674298

5. Miner Safety Review Manuscript
Miner J Pooled Phase III safety analysis of sufentanil sublingual tablets for short-term treatment of moderate-to-severe acute pain. J Pain Management. 2019 epub ahead of print.

https://www.futuremedicine.com/doi/10.2217/pmt-2018-0090


ZALVISO®

ZALVISO is an investigational drug. It is not approved by the FDA. AcelRx makes no claims regarding the safety or effectiveness of ZALVISO.

1. ZALVISO PK Manuscript
Willsie SK, Evashenk MA, Hamel LG, Hwang SS, Chiang YK, Palmer PP. Pharmacokinetic Properties of Single- and Repeated-Dose Sufentanil Sublingual Tablets in Healthy Volunteers. Clin Ther. 2015;37(1): 145-155.

http://www.clinicaltherapeutics.com/article/S0149-2918(14)00733-4/abstract

2. Primary Manuscript for Phase 3 ZALVISO study IAP309
Melson TI, Boyer DL, Minkowitz HS, Turan A, Chiang YK, Evashenk MA, Palmer PP. Sufentanil Sublingual Tablet System vs. Intravenous Patient-Controlled Analgesia with Morphine for Postoperative Pain Control: A Randomized, Active-Comparator Trial. Pain Pract. 2014;14(8):679-688.

https://www.ncbi.nlm.nih.gov/pubmed/25155134

3. Primary Manuscript for Phase 3 ZALVISO study IAP310
Ringold FG, Minkowitz HS, Gan TJ, et al. Sufentanil Sublingual Tablet System for the Management of Postoperative Pain Following Open Abdominal Surgery: A Randomized, Placebo-Controlled Study. Reg Anesth Pain Med. 2015;40(1):22–30.

http://journals.lww.com/rapm/Citation/2015/01000/Sufentanil_Sublingual_Tablet_System_for_the.5.aspx

4. Primary Manuscript for Phase 3 ZALVISO study IAP311
Jove M, Griffin DW, Minkowitz HS, Ben-David B, Evashenk MA, Palmer PP. Sufentanil Sublingual Tablet System for the Management of Postoperative Pain after Knee or Hip Arthroplasty: A Randomized, Placebo-Controlled Study. Anesthesiol. 2015; 123(2):434-443.

http://anesthesiology.pubs.asahq.org/article.aspx?articleid=2343031


Health Economics and Outcomes Research Articles

1. HEOR Study – Cost of IV Analgesia in the Emergency Department
Palmer PP, Walker JA, Patanwala AE, Hagberg CA, House JA. Cost of Intravenous Analgesia for the Management of Acute Pain in the Emergency Department is Substantial in the United States. J Health Econ Outcomes Res. 2017;5(1):1-15.

https://www.jheor.org/other-conditions/237-cost-of-intravenous-analgesia-for-the-management-of-acute-pain-in-the-emergency-department-is-substantial-in-the-united-states

2. HEOR Study – Cost of IV Morphine in the EU
Casamayor M, DiDonato K, Hennebert M, Brazzi L, Prosen G. Administration of intravenous morphine for acute pain in the emergency department inflicts an economic burden in Europe. Drugs Context. 2018;7:212524

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898605/

3. HEOR Study – Cost of IV PCA
Palmer P, Ji X, Stephens J. Cost of Opioid Intravenous Patient-controlled analgesia: results from a hospital database analysis and literature assessment. Clinicoecon Outcomes Res. 2014;6:311-318.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4073913/